Acorn Baking News Today

Manischewitz is recalling Manischewitz Dark Chocolate Coins as they may contain undeclared milk, a known allergen, according to the U.S Food and Drug Administration or FDA.

This weeks Recall Roundup includes whey protein bars with foreign material, stone fruit with listeria, cooktops that can stay on and heated blankets that can cause fires.

Consumer confidence survey results from Germany and France are due on Tuesday, headlining a busy day for the European economic news. At 2.00 am ET, the market research group Gfk is scheduled to issue Germany's consumer confidence survey results.

Greencore Group plc (GNC.L) reported that its fiscal 2023 profit before taxation increased to 45.2 million pounds from 39.8 million pounds, last year, driven by higher operating profit and lower exceptional items offset by higher finance costs.

Wine Country Gift Baskets is recalling all gift baskets produced with Acorn Baking Co. branded raspberry creme filled cookies, citing the possible presence of hazelnut, a tree nut allergen, the U.

The Distributive Trades survey data from the UK is due on Monday, headlining a light day for the European economic news. At 2.00 am ET, Statistics Norway releases retail sales and household spending data.

Check-Cap Ltd. (CHEK) posted a third quarter net loss of $2.6 million, compared to a loss of $4.7 million, last year. Loss per share was $0.44 compared to a loss of $0.

German export expectations improved in November, survey data from the ifo institute showed Monday. The ifo export expectations indicator climbed to minus 3.8 points in November from minus 6.

Biotechnology company Krystal Biotech, Inc. (KRYS) announced Monday that the Company's Marketing Authorization Application (MAA) to the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) for VYJUVEK (beremagene geperpavec-svdt or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB) has been validated and is now under CHMP review.

Immuno-oncology company Genelux Corp. (GNLX) announced Monday that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development program of Olvi-Vec (olvimulogene nanivacirepvec) for the treatment of patients with platinum resistant/refractory ovarian cancer.